AZN.UK

10,440

-1.75%↓

GSK

1,407

-3.27%↓

INDV

1,132

+1.16%↑

AZN.UK

10,440

-1.75%↓

GSK

1,407

-3.27%↓

INDV

1,132

+1.16%↑

AZN.UK

10,440

-1.75%↓

GSK

1,407

-3.27%↓

INDV

1,132

+1.16%↑

AZN.UK

10,440

-1.75%↓

GSK

1,407

-3.27%↓

INDV

1,132

+1.16%↑

AZN.UK

10,440

-1.75%↓

GSK

1,407

-3.27%↓

INDV

1,132

+1.16%↑

Search

Oxford Biomedica PLC

Geschlossen

351.5 -0.57

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

346.5

Max

357.5

Schlüsselkennzahlen

By Trading Economics

Einkommen

-11M

Verkäufe

78M

EPS

-0.077

Gewinnspanne

-13.726

Angestellte

850

EBITDA

5M

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+59.61% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

22. Sept. 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

356M

Vorheriger Eröffnungskurs

352.07

Vorheriger Schlusskurs

351.5

Oxford Biomedica PLC Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

11. Juli 2025, 22:19 UTC

Akquisitionen, Fusionen, Übernahmen

FCC Approves U.S. Cellular Sale to T-Mobile

11. Juli 2025, 17:28 UTC

Wichtige Markttreiber

SharpLink Gaming Gains on Ethereum Purchase

11. Juli 2025, 16:57 UTC

Ergebnisse

BASF Cuts Outlook on Global Economy Uncertainty

11. Juli 2025, 21:45 UTC

Market Talk

Fitch Affirms Germany's Rating, Sees Deficit, Debt Rising -- Market Talk

11. Juli 2025, 19:46 UTC

Akquisitionen, Fusionen, Übernahmen

Kraft Heinz Might Split Up, Report Says. What Investors Need to Know. -- Barrons.com

11. Juli 2025, 19:45 UTC

Market Talk

Crude Futures Post Back-to-Back Weekly Gains -- Market Talk

11. Juli 2025, 19:05 UTC

Market Talk

U.S. Natural Gas Futures Post Third Straight Weekly Loss -- Market Talk

11. Juli 2025, 18:18 UTC

Market Talk

Canada Officials Tight-Lipped on Next Steps in Trump Trade Talks -- Market Talk

11. Juli 2025, 17:35 UTC

Market Talk

Canada Should Target Lower Sectoral Tariffs, Import Quotas in US Trade Talks -- Market Talk

11. Juli 2025, 17:26 UTC

Market Talk

U.S. Oil Rig Count Down by 1 to 424 -- Market Talk

11. Juli 2025, 16:53 UTC

Market Talk

Crude Futures Add to Early Gains -- Market Talk

11. Juli 2025, 16:42 UTC

Ergebnisse

BASF Cuts Outlook on Global Economic Uncertainty

11. Juli 2025, 16:08 UTC

Market Talk

Rise in Canadian Staycations May Help Explain Labor Market Strength -- Market Talk

11. Juli 2025, 16:05 UTC

Ergebnisse

BASF Will Publish Half-Year Results on July 30

11. Juli 2025, 16:04 UTC

Market Talk

Global Equities Roundup: Market Talk

11. Juli 2025, 16:04 UTC

Market Talk

Senior Housing Shortage Gives REITs Pricing Power -- Market Talk

11. Juli 2025, 16:03 UTC

Ergebnisse

BASF: Guidance Cut Is Due to Ongoing Macroeconomic, Geopolitical Uncertainties

11. Juli 2025, 16:02 UTC

Ergebnisse

BASF Continues to Expect Free Cash Flow Between EUR400M and EUR800M in 2025

11. Juli 2025, 16:01 UTC

Ergebnisse

BASF Had Seen Ebitda Before Special Items Between EUR8B and EUR8.4B in 2025

11. Juli 2025, 16:00 UTC

Ergebnisse

BASF Now Sees Ebitda Before Special Items Between EUR7.3B and EUR7.7B in 2025

11. Juli 2025, 15:59 UTC

Ergebnisse

BASF Cuts 2025 Earnings View

11. Juli 2025, 15:58 UTC

Ergebnisse

Nvidia's CEO Has Sold a Million Shares. He Has Millions More to Sell. -- Barrons.com

11. Juli 2025, 15:57 UTC

Ergebnisse

BASF 2Q EBIT Before Special Items EUR810M

11. Juli 2025, 15:54 UTC

Ergebnisse

BASF: Analysts Had Expected 2Q Sales of EUR15.80B

11. Juli 2025, 15:54 UTC

Ergebnisse

BASF 2Q Sales Fell 2.1% on Year

11. Juli 2025, 15:53 UTC

Ergebnisse

BASF 2Q Sales EUR15.77B

11. Juli 2025, 15:52 UTC

Ergebnisse

BASF: This Was in Line With Consensus Estimates

11. Juli 2025, 15:52 UTC

Ergebnisse

BASF 2Q Ebitda Before Special Items EUR1.77B

11. Juli 2025, 15:49 UTC

Ergebnisse

BASF Reports Preliminary 2Q Figures, Adjusts 2025 Outlook

11. Juli 2025, 15:41 UTC

Market Talk

Oil, Gas Prices Not Seen Supporting Drilling Boom -- Market Talk

Peer-Vergleich

Kursveränderung

Oxford Biomedica PLC Prognose

Kursziel

By TipRanks

59.61% Vorteil

12-Monats-Prognose

Durchschnitt 563.438 GBX  59.61%

Hoch 800 GBX

Tief 324 GBX

Basierend auf 3 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Oxford Biomedica PLC – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

3 ratings

2

Buy

1

Halten

0

Sell

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Oxford Biomedica PLC

Oxford Biomedica plc, a contract development and manufacturing organization, focuses on delivering therapies to patients worldwide. Its LentiVector platform technology is a lentiviral vector based gene delivery system which is designed to overcome the safety and delivery problems associated with earlier generations of vector systems. The company operates in two segments, Platform and Product. The Platform segment engages in bioprocessing and process development activities for third parties. The Product segment is involved in the research and development of new gene therapeutic product candidates. The company collaborates with pharmaceutical and biotechnology companies providing viral vector development and manufacturing services in lentivirus, adeno-associated virus, adenoviral vectors, and other viral vector types. The company was formerly known as Pinco 838 Limited and changed its name to Oxford Biomedica plc in October 1996. Oxford Biomedica plc was incorporated in 1996 and is headquartered in Oxford, the United Kingdom.